US20040208886A1 - Composition comprising a parvovirus vp1- variant and a parvovirus ns1 protein for induction of cytolysis - Google Patents
Composition comprising a parvovirus vp1- variant and a parvovirus ns1 protein for induction of cytolysis Download PDFInfo
- Publication number
- US20040208886A1 US20040208886A1 US10/483,234 US48323404A US2004208886A1 US 20040208886 A1 US20040208886 A1 US 20040208886A1 US 48323404 A US48323404 A US 48323404A US 2004208886 A1 US2004208886 A1 US 2004208886A1
- Authority
- US
- United States
- Prior art keywords
- protein
- composition
- parvovirus
- dna sequence
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 241000125945 Protoparvovirus Species 0.000 title claims abstract description 34
- 108700038653 parvovirus NS1 Proteins 0.000 title claims abstract description 8
- 206010057248 Cell death Diseases 0.000 title description 4
- 230000009089 cytolysis Effects 0.000 title description 4
- 230000006698 induction Effects 0.000 title description 4
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 61
- 101710197658 Capsid protein VP1 Proteins 0.000 claims abstract description 61
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims abstract description 61
- 101710108545 Viral protein 1 Proteins 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000001173 tumoral effect Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000005090 green fluorescent protein Substances 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 102000015439 Phospholipases Human genes 0.000 claims description 4
- 108010064785 Phospholipases Proteins 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 abstract description 7
- 231100000765 toxin Toxicity 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 41
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 38
- 101710128560 Initiator protein NS1 Proteins 0.000 description 38
- 101710144127 Non-structural protein 1 Proteins 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 239000012634 fragment Substances 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- 241000702623 Minute virus of mice Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 6
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 101710081079 Minor spike protein H Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000702620 H-1 parvovirus Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000005904 anticancer immunity Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010048669 Terminal state Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000002985 oncosuppressive effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a composition
- a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention relates to DNA sequences encoding said proteins.
- the composition of the invention is useful for the preparation of a toxin for treating tumoral. diseases.
- Parvovirus designates a genus of the virus family Parvoviridae.
- the parvovirus genus comprises a number of small, icosaedric viruses that can replicate in the absence of a helper virus.
- Parvovirus contains a single-stranded DNA having a length of about 5.000 bp. At the 3′ and 5′ ends of the DNA there is one palindromic sequence each.
- the DNA codes for two capsid proteins, VP1 and VP2, as well as for two regulatory non-structure proteins, NS-1 and NS-2. The latter proteins are phosphorylated and show nuclear or both cytoplasmic and nuclear localization, respectively.
- the two capsid proteins VP1 and VP2 are encoded by overlapping open reading frames so that the VP2 encoding region is entirely comprised within the VP1 encoding region.
- capsid proteins are expressed in a VP1:VP2 ratio of 1:10 due to alternative splicing.
- the region of the capsid proteins which is specific for VP1 contains motifs common to cellular phospholipase A and indeed exerts this activity in vitro.
- the calcium dependent, secreted PLA 2 to which parvovirus VP1 shares similarities, takes part in signaling pathways that involve cell lysis by permeabilizing membranes.
- NS1 has been shown to be regulated by members of the protein kinase C family, which in turn are subject to regulation through phospholipases.
- Parvoviruses are usually well-tolerated by populations of their natural host, in which they persist without apparent pathological signs. This is due to both the protection of foetuses and neonates by maternal immunity, and the striking restriction of parvovirus replication to a narrow range of target proliferating tissues in adult animals. This host tolerance concerns especially rodent parvoviruses, for example the minute virus of mice (MVM) and H-1 virus in their respective natural hosts, namely mice and rats. In addition, humans can be infected with the latter viruses, without any evidence of associated deleterious effects from existing epidemiological studies and clinical trials. On the other hand, autonomous parvoviruses have been shown to preferentially propagate in and to kill neoplastically transformed cells.
- viruses consist of a class of viruses that, despite causing viremia in their infected hosts, mostly produce an apathogenic infection.
- autonomous parvoviruses are thought to be excellent tools for cancer gene therapy.
- Particular interests are focused on recombinant vectors maintaining their natural oncotropism, as well as their oncolytic and oncosuppressive potential.
- NS1 the major non-structural protein is necessary for viral DNA replication and participates in the regulation of viral gene expression. Particularly, NS1 transactivates the promoter P38 and exhibits DNA-binding, helicase and DNA-nicking activities. Furthermore, NS1 induces cytotoxic and/or cytostatic stress in sensitive host cells.
- NS1 within parvoviral vectors, in order to (a) maintain their specific competence for NS1-dependent DNA replication and gene expression in tumour cells, resulting in an enhanced production of therapeutics agents at the desired locus (oncotropism), (b) take advantage of NS1 cytotoxicity to kill neoplastic cells and shed tumour antigens to elicit anti-cancer immunity (oncolysis), and (c) achieve still unknown effects that may contribute to the persistence (memory) of a tumour-free status (oncosuppression).
- NS1 variants have been produced by site-directed mutagenesis of putative regulatory elements, which are up and down-modulated regarding their cytotoxic potential while keeping replicative functions (European patent application No. 99115161.4). These variants may allow a prolongated expression of transgenes harbored by parvoviral vectors (less toxic variants) or endow infectious parvoviruses with an enhanced oncotoxicity (more toxic variants).
- NS1 as an oncotoxin in the context of parvoviral, but also non-parvoviral vectors it should be stated that, though able to induce apoptosis in certain cancer cells (leukemias), NS1 alone often causes only a cytostatic effect that is accompanied by morphological changes (cell shrinking) and a dramatic disorganisation of the cytoskeleton in the absence of cell lysis or apoptotic signs. NS1-expressing cells remain on a long-term in this state that has, thus, common features with a terminal differentiation.
- NS1-mediated induction of a cellular terminal state is interesting on its own right for limiting tumour cell proliferation, yet it is not suitable to trigger the uptake of tumour-associated antigens (TAAs) by presenting cells of the immune system, which requires tumour cell death.
- TAAs tumour-associated antigens
- the present invention is based on the applicant's finding of a new toxin which is a combination of two parvoviral products, the NS1 protein and the capsid VP1 protein or a part thereof. Since VP1 is a large protein (83 kDa, 2453 bp ORF) which is itself subject to regulation (it is post translationally modified), small fusion proteins were constructed containing a VP1-specific region and expressed together with the effector protein NS1 upon transfection in mammalian cells.
- the fusion proteins significantly increased the intrinsic cytotoxicity of NS1 as measured by the disappearance of VP1/NS1 containing cells in a function of time (monitored by fluorescent proteins present in transfected cells; see FIG. 1.). This increased toxicity is manifested in an induction of cytolysis as apparent by the release of lactate dehydrogenase (LDH) in the presence of both wild type NSI and the VPI specific region, a feature that is absent upon the sole expression of wildtype NSI (FIG. 4).
- LDH lactate dehydrogenase
- the applicant's findings are used to provide a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
- parvovirus comprises any parvovirus, particularly a rodent parvovirus, such as minute virus of mice (MVM) and H-1 virus.
- NS1 protein comprises any NS1 protein, i.e. the native protein obtainable form the parvoviruses described above as well as modified versions thereof which are biologically active (see, e.g., Genebank Accession No: PO3134; Astell et al., Nucleic Acids Res. 11 (1983), 999-1018). Such modified versions of the NS1 protein also comprise the mutants disclosed in the European patent application No. 99115161.4.
- VP1 protein comprises any VP1 protein, i.e. the native protein obtainable from the parvoviruses described above as well as modified versions and fusion proteins which are still biologically active (see, e.g., Genebank Accession No: PO3137; Astell et al., Nucleic Acids Res. 11 (1983), 999-1018). Examples of modified versions are truncated and mutant forms of the VP1 protein.
- the expression “comprising a parvovirus NS1 protein and a parvovirus VP1 protein” also comprises NS1-VP1 fusion proteins.
- NS1-VP1 fusion proteins comprise any NS1-VP1 fusion protein which exhibits the biological activity of both protein partners.
- the NS1 protein corresponds to the N-terminal partner of the fusion protein.
- DNA sequences encoding such proteins can be designed by the person skilled in the art by well known methods. The person skilled in the art is also in a position to design DNA sequences encoding a fusion protein, wherein the NS1- and VP1-protein, respectively, is (are) truncated but still active.
- Assays for monitoring the biological activities of the proteins are well known to the person skilled in the art and can be carried like measurements of arachidonic acid release (Balsinde et al., PNAS USA 95 (1998), 7951-7956) or production of prostaglandin E2 (Newton et al., 1998 , IBC 48, 32312-21) or as described in Example 2, below.
- the VP1 protein is fused to a carrier protein allowing, e.g., to detect the expression of the VP1 protein in a host cell.
- a carrier protein e.g., to detect the expression of the VP1 protein in a host cell.
- Particularly preferred are the carrier proteins green fluorescent protein (GFP), NS1, IL-2, IP10, Cytatines, Cro, or signaling peptides targeting the protein to distinct locations within the cell.
- the VP1 protein (or the VP1 partner of the fusion protein) is a truncated protein which still exhibits the desired biological activity.
- truncated versions of the VP1 protein can be generated by the person skilled in the art according to standard methods.
- the biological activity of the VP1 fragments can be assayed, e.g. by the method described in Example 2, below.
- the truncated VP1 protein comprises the VP1 domain exhibiting phospholipase A activity. This activity is localised within the pecific N-terminal part of the VP1 protein (residues 1 to 142) (see FIG. 2; Zadori et al. (2000), VIIIth Parvovirus Workshop Mont Tremblant, Quebec, Canada.)
- a further subject matter of the present invention relates to (a) DNA sequence(s) encoding the proteins of the composition of the invention described above.
- a DNA sequence according to the present invention can be present in a vector and expression vector, respectively.
- a person skilled in the art is familiar with examples thereof.
- an expression vector for E. coli these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b, T7 based expression vectors and pQE-8.
- yeast e.g. pY100 and Ycpad1 have to be mentioned while e.g. pKCR, pEFBOS, cDM8, pMSCND, and pCEV4 have to be indicated for the expression in animal cells.
- the baculovirus expression vector pAcSGHisNT-A is especially suitable for the expression in insect cells.
- the vector containing the DNA sequence(s) according to the invention is a virus, e.g. an adenovirus, vaccinia virus, an AAV virus or a parvovirus, such as MVM or H-1, a parvovirus being preferred.
- the vector may also be a retrovirus, such as MOMULV, MoMuLV, HaMuSV, MUMTV, RSV or GaLV.
- Suitable promoters include the strong constitutive human or mouse cytomegalovirus (CMV) immediate early promoter, the inducible P38 parvovirus promoter, the parvovirus P4 promoter and tissue and tumour specific promoters.
- the present invention relates to host cells which contain the above described vectors.
- host cells include bacteria, yeast, insect and animal cells, preferably mammalian cells.
- the E. coli strains HB101, DH1, x1776, JM101, JM109, BL21, XL1Blue and SG 13009, the yeast strain Saccharomyces cerevisiae and the animal cells L, A9, 3T3, FM3A, CHO, COS, Vero, HeLa and the insect cells sf9 are preferred.
- Methods of transforming these host cells, of phenotypically selecting transformants and of expressing the DNA according to the invention by using the above described vectors are known in the art.
- the present invention also relates to a method of producing the composition of the invention comprising the culturing of the transformant described above under suitable conditions and isolating the protein(s) of the composition from the transformant or the medium. Methods for culturing said transformants, isolating and purifying the protein(s) are well known to the person skilled in the art.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the above described compounds.
- these compounds are preferably combined with suitable pharmaceutical carriers.
- suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
- Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose.
- Administration of the composition may be effected by different ways, e.g. by intravenous, intraperetoneal, subcutaneous, intramuscular, topical or intradermal administration. The route of administration, of course, depends on the nature of the disease, e.g.
- dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends on many factors, including the patient's size, body surface area, age, sex, the particular compound to be administered, time and route of administration, the kind of the tumour, general health and other drugs being administered concurrently.
- composition of the present invention can be administered in the form of proteins (protein injection or protein delivery into the desired tumour cells) or (a) genetic element(s) encoding said proteins, supplied as free molecules or through a viral, e.g. parvoviral, or non-viral vector.
- a viral e.g. parvoviral, or non-viral vector.
- Suitable vectors and methods for in vitro- or in vivo-gene therapy are described in the literature and are known to the persons skilled in the art; see, e.g., WO 94/29469 or WO 97/00957.
- the DNA sequences encoding the proteins of the composition of the present invention can be administered directly to the target site, e.g., by ballistic delivery, as a colloidal dispersion system or by catheter to a site in artery.
- the colloidal dispersion systems which can be used for delivery of the above DNA sequences include macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, (mixed) micelles, liposomes and lipoplexes.
- the preferred colloidal system is a liposome.
- the composition of the liposome is usually a combination of phospholipids and steroids, especially cholesterol.
- the skilled person is in a position to select such liposomes which are suitable for the delivery of the desired DNA molecule.
- Organ-specific or cell-specific liposomes can be used, e.g. in order to achieve delivery only to the desired tissue.
- the targeting of liposomes can be carried out by the person skilled in the art by applying commonly known methods.
- This targeting includes passive targeting (utilising the natural tendency of the liposomes to distribute to cells of the RES in organs which contain sinusoidal capillaries) or active targeting (for example by coupling the liposome to a specific ligand, e.g., an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods).
- a specific ligand e.g., an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods.
- monoclonal antibodies are preferably used to target liposomes to specific tumours via specific cell-surface ligands.
- the treatment can be given to cell cultures or organisms, e.g. tumour bearing organisms. Should both proteins of the present invention be administered as separated genetic elements, time intervals between their respective administration can be applied. Alternatively, stably transfected cell lines expressing the VP1 protein can be produced. In the absence of NS1, the VP1 component is well tolerated by host cells over extended periods of time. The cytolytic effect is exerted only when the VP1 component is coexpressed with the NS1 component. It is, thus, possible to select tumour cell lines that stably express the VP1 component and contain (or not) an inducible clone of the NS1 component that is kept silent.
- tumour cells Upon NS1 expression (as a result of NS1 gene transfer or induction) the tumour cells get lyzed, which can be achieved in vitro or in vivo (after transplantation of VP1 expressing cells) in order to trigger the release, uptake and presentation of tumour-associated antigens.
- composition of the invention or the corresponding DNA sequences can be applied in combination with other agents (such as cytokines) in gene and cancer therapy approaches.
- the present invention relates to the use of the above described compounds (protein composition, DNA sequences or expression vectors) for the preparation of a toxin for treating tumoral diseases.
- FIG. 1 A9 cells grown on Spot-Slides (NeoLab. Heidelberg, Germany) were transfected with the indicated constructs (100 ng/well) using 1 ⁇ L Lipofectamine (GibcoBRL, Düsseldorf, Germany). Transfected, living cells were identified by their green fluorescence and monitored in daily intervals using a reverse angle fluorescence Microscope (Leica IL2).
- Transfected, GFP expressing (fluorescent) cells were counted at daily intervals and their survival was expressed as percentage of the number of fluorescent cells at day 2 post transfection.
- the gene for the green fluorescent protein was fused to the PLA 2 domain.
- the phosphorylation site mutant NS1:S473A (Dettwiler et al., J.Virol.
- Mutant PLA 2 was generated by PCR replacing the HD-motif (aa 41/42), i.e. the active site of the PLA 2 enzyme, by methionine residues. Toxicity assay was carried out according to Corbau et al., Virology 278 (2000), 151-167.
- wild type NS1 and the PLA 2 -domain of VP1 acted synergistically in that this cytotoxicity of coexpressed active polypeptides was in comparison with the effect of each effector protein alone, as revealed by the disappearance of fluorescent/transfected cells.
- FIG. 2 Schematic representation of the Darvovirus VP proteins
- VP1 the large 83 kDa capsid protein comprises 716 amino acids while VP2 lacks the 142 N-terminal amino acids and starts at methionine 143 due to alternative splicing of the precursor mRNAs.
- the VP1 unique region is represented as a hatched box.
- the four motifs showing homology to cellular PLA 2 s are indicated as crossed regions and the corresponding amino acid sequences of VP1 are given on the bottom.
- the putative active site for PLA 2 -activity is indicated by capitals.
- FIG. 3 Schematic representation of examples of VP1 and VP1 variants designed for use of the present invention
- LDH is a cytosolic enzyme that is released upon cell lysis. Released LDH is measured using an enzymatic assay which results in the conversion of a tetrazolium salt (INT) into a red formazan product.
- INT tetrazolium salt
- the colour intensity measured with a standard 96 well plate reader at 490 nm, is proportional to the number of lysed cells.
- Infection was carried out 24 hours after spreading of the cells at a multiplicity of 10 infectious units of virus per cell. Culture medium was collected 6 days after transfection and directly tested for LDH activity as described by the manufacturer. The total amount of LDH in the cells stands for 100%
- the coding sequence for the VP1-GFP fusion protein was obtained by chimeric polymerase chain reaction (PCR) using the primer pair 5′-ATG ACT CCA TGG CGC CTC CAG CTA AAA AGA-3′ (A) and 5′-TCG CCC TTG CTC ACC ATC GTT TGA CTC CTT TGC TG-3′ (B) using as template pTM1-VP1 to obtain the coding sequence for the VP1-specific domain of parvovirus VP-proteins.
- the primer pair 5′-AGG AGT CAA ACG ATG GTG AGC AAG GGC GAG GAG-3′ (C) and 5′-ACG GTC TCG AGT AGC GAC CGG CGC TCA GTT GG-3′ (D) with pEGFP (Clontech, Heidelberg, Germany) as a template was used to obtain the GFP encoding sequence.
- the VP1- and GFP-fragments were annealed due to overlapping sequences and further amplified using primers A and D.
- the PCR product was digested with the restriction endonucleases NcoI and XbaI and ligated into the similarly cleaved vector pDB-MVMp; see FIG. 1C.
- pDB-MVMp constitutes an infectious molecular clone of MVMp (Kestler et al., Hum. Gene Ther. 10 (1999), 1619-1632).
- the construct constitutes an eukaryotic expression vector under the control of the parvovirus P4 promoter (S-phase/transformation regulated).
- the coding sequence for the NS1-VP1 fusion protein was obtained by chimeric PCR using the primer pair 5′-GGT CAA TCT ATT CGC ATT GAT-3′ (A) and 5′-GAG GCG CCA TGT CCA AGT TCA GCG GCT CGC-3′ (B) for amplification of the template pTM1-NS1 Nuesch et al., Virology 191 (1992), 406-416) to obtain the full-length NS1 fragment.
- the primer pair 5′-GAA CTT GGA CAT GGC GCC TCC AGC TAA AAG-3′ (C) and 5′-ATA CGC CCG GGC TAG GTT TGA CTG CTT TGC TGT-3′ (D) with pTM1-VP1 as a template was used for obtaining the VP1 coding sequence.
- the two fragments were combined using primers A and D.
- the PCR product was digested with the restriction endonucleases XhoI and SmaI and ligated into XhoI and StuI digested vector pTHis-NS1 (Nuesch et al., Virology 209 (1995), 122-135).
- telomere sequence of the NS1-VP1 variant was amplified by PCR using an N-terminal primer containing a SmaI restriction site together with a C-terminal primer containing an XbaI cleavage site.
- This SmaI to XbaI NS1-VP1 fragment wad then transferred into EcoRV and XbaI cleaved pP4-GFP.
- Clone pP4-NS1-VP1 was deposited on May 15, 2001, with the DSMZ under accession number DSM 14300 according to the regulations of the Budapest treaty.
- pP4-NS1+2-P4-VP1-GFP recombinant MVM virus the P4-VP1-GFP fragment was amplified using a primer 5′-ATA CGA GAT CTG TTT AAA CCA AGG CGC GAA AAG G-3′ within the P4 promoter region containing an N-terminal BglII cleavage site and primer D wihtin the C-terminus of GFP harbouring an XbaI site.
- This BglII to XbaI fragment was then cloned into the BglII and XbaI cleaved capsid region of pDB-MVMp.
- Clone pP4-NS1+2-P4-VP1-GFP was deposited on May 15, 2001, with the DSMZ under accession number DSM 14301 according to the regulations of the Budapest treaty.
- A9 cells grown on Spot slides were transfected with the constructs described in Example 1, above, and shown in FIGS. 1C and 3 expressing the GFP (fusion) proteins using lipofectamine. Fluorescent cells were monitored in daily intervals for their overall structure. From the results shown in FIG. 1B it can be concluded that NS1 and VP1 fusion proteins act synergistically to kill the transfected A9 cells. Experimental details are given in the legend of FIG. 1.
- A9 cells were transduced with various multiplicities of recombinant parvoviruses containing VP1-variants or mutants thereof.
- endogenous LDH lactate dehydrogenase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.
Description
- The present invention relates to a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention relates to DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral. diseases.
- Parvovirus designates a genus of the virus family Parvoviridae. The parvovirus genus comprises a number of small, icosaedric viruses that can replicate in the absence of a helper virus. Parvovirus contains a single-stranded DNA having a length of about 5.000 bp. At the 3′ and 5′ ends of the DNA there is one palindromic sequence each. The DNA codes for two capsid proteins, VP1 and VP2, as well as for two regulatory non-structure proteins, NS-1 and NS-2. The latter proteins are phosphorylated and show nuclear or both cytoplasmic and nuclear localization, respectively. The two capsid proteins VP1 and VP2 are encoded by overlapping open reading frames so that the VP2 encoding region is entirely comprised within the VP1 encoding region. In a natural infection capsid proteins are expressed in a VP1:VP2 ratio of 1:10 due to alternative splicing. Recently it has been shown that the region of the capsid proteins which is specific for VP1 (N-terminal region) contains motifs common to cellular phospholipase A and indeed exerts this activity in vitro. The calcium dependent, secreted PLA2 to which parvovirus VP1 shares similarities, takes part in signaling pathways that involve cell lysis by permeabilizing membranes. On the other hand, NS1 has been shown to be regulated by members of the protein kinase C family, which in turn are subject to regulation through phospholipases.
- Parvoviruses are usually well-tolerated by populations of their natural host, in which they persist without apparent pathological signs. This is due to both the protection of foetuses and neonates by maternal immunity, and the striking restriction of parvovirus replication to a narrow range of target proliferating tissues in adult animals. This host tolerance concerns especially rodent parvoviruses, for example the minute virus of mice (MVM) and H-1 virus in their respective natural hosts, namely mice and rats. In addition, humans can be infected with the latter viruses, without any evidence of associated deleterious effects from existing epidemiological studies and clinical trials. On the other hand, autonomous parvoviruses have been shown to preferentially propagate in and to kill neoplastically transformed cells. In addition, they consist of a class of viruses that, despite causing viremia in their infected hosts, mostly produce an apathogenic infection. For these reasons, autonomous parvoviruses are thought to be excellent tools for cancer gene therapy. Particular interests are focused on recombinant vectors maintaining their natural oncotropism, as well as their oncolytic and oncosuppressive potential.
- NS1, the major non-structural protein is necessary for viral DNA replication and participates in the regulation of viral gene expression. Particularly, NS1 transactivates the promoter P38 and exhibits DNA-binding, helicase and DNA-nicking activities. Furthermore, NS1 induces cytotoxic and/or cytostatic stress in sensitive host cells.
- Therefore, it seems advisable to keep NS1 within parvoviral vectors, in order to (a) maintain their specific competence for NS1-dependent DNA replication and gene expression in tumour cells, resulting in an enhanced production of therapeutics agents at the desired locus (oncotropism), (b) take advantage of NS1 cytotoxicity to kill neoplastic cells and shed tumour antigens to elicit anti-cancer immunity (oncolysis), and (c) achieve still unknown effects that may contribute to the persistence (memory) of a tumour-free status (oncosuppression).
- Current parvoviral vectors harbor the wild type genes (for the above discussed reasons) and either of a variety of different transgenes aimed to induce anti-tumoral responses. In most applications considered to date, the transgenes were chosen for their capacity to upmodulate the host cellular immunity against cancer. While the transgene expression induced by such vectors was successfully targeted at the location of the tumour and was especially high, duration of the therapy was relatively short, i.e. three to five days, which is likely due to the NS1-induced killing of transduced cells. New developments concerning the regulation of the NS1 protein have shown that the cytotoxicity of this protein is a regulated process. Furthermore, NS1 variants have been produced by site-directed mutagenesis of putative regulatory elements, which are up and down-modulated regarding their cytotoxic potential while keeping replicative functions (European patent application No. 99115161.4). These variants may allow a prolongated expression of transgenes harbored by parvoviral vectors (less toxic variants) or endow infectious parvoviruses with an enhanced oncotoxicity (more toxic variants).
- Considering the use of NS1 as an oncotoxin in the context of parvoviral, but also non-parvoviral vectors it should be stated that, though able to induce apoptosis in certain cancer cells (leukemias), NS1 alone often causes only a cytostatic effect that is accompanied by morphological changes (cell shrinking) and a dramatic disorganisation of the cytoskeleton in the absence of cell lysis or apoptotic signs. NS1-expressing cells remain on a long-term in this state that has, thus, common features with a terminal differentiation. This NS1-mediated induction of a cellular terminal state is interesting on its own right for limiting tumour cell proliferation, yet it is not suitable to trigger the uptake of tumour-associated antigens (TAAs) by presenting cells of the immune system, which requires tumour cell death. This is a very serious limitation of the use of NS1 alone: Given that only a minor fraction of tumour cells can be expected to be killed, it is crucial that the direct toxicity of the vector (affecting only transduced cells) is enhanced by the immune system in order to achieve a bystander suppressive effect on non-infected tumour cells.
- Therefore, it is the object of the present invention to provide a means for improving the therapeutic usefulness of NS1, e.g. as regards the NS1 cytotoxicity to kill neoplastic cells and shed tumour antigens to elicit anti-cancer immunity.
- According to the invention this is achieved by the subject matters defined in the claims.
- The present invention is based on the applicant's finding of a new toxin which is a combination of two parvoviral products, the NS1 protein and the capsid VP1 protein or a part thereof. Since VP1 is a large protein (83 kDa, 2453 bp ORF) which is itself subject to regulation (it is post translationally modified), small fusion proteins were constructed containing a VP1-specific region and expressed together with the effector protein NS1 upon transfection in mammalian cells. While being well tolerated by the cells on their own, the fusion proteins significantly increased the intrinsic cytotoxicity of NS1 as measured by the disappearance of VP1/NS1 containing cells in a function of time (monitored by fluorescent proteins present in transfected cells; see FIG. 1.). This increased toxicity is manifested in an induction of cytolysis as apparent by the release of lactate dehydrogenase (LDH) in the presence of both wild type NSI and the VPI specific region, a feature that is absent upon the sole expression of wildtype NSI (FIG. 4). In this regard it has to be stated that the toxic effects of NSI and VPI could be mutual in a way that not only VPI is increasing NSI toxicity, but also that NSI is able to activate VPI induced cytolysis. To conclude, this new toxin is endowed with an enhanced capacity for causing cell death and not merely cell proliferation arrest. In the cellular system analysed, the NS1-VP1 toxin proved to have an enhanced lytic activity. Thus, tumorally expressed NS1-VP1 toxin is endowed with an enhanced capacity to kill tumour cells, which in its turn should stimulate the loading of presenting cells with TAAs and the activation of an anticancer immune response.
- According to the present invention, the applicant's findings are used to provide a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
- The expression “parvovirus” comprises any parvovirus, particularly a rodent parvovirus, such as minute virus of mice (MVM) and H-1 virus.
- The expression “NS1 protein” comprises any NS1 protein, i.e. the native protein obtainable form the parvoviruses described above as well as modified versions thereof which are biologically active (see, e.g., Genebank Accession No: PO3134; Astell et al., Nucleic Acids Res. 11 (1983), 999-1018). Such modified versions of the NS1 protein also comprise the mutants disclosed in the European patent application No. 99115161.4.
- The expression “VP1 protein” comprises any VP1 protein, i.e. the native protein obtainable from the parvoviruses described above as well as modified versions and fusion proteins which are still biologically active (see, e.g., Genebank Accession No: PO3137; Astell et al., Nucleic Acids Res. 11 (1983), 999-1018). Examples of modified versions are truncated and mutant forms of the VP1 protein.
- The expression “comprising a parvovirus NS1 protein and a parvovirus VP1 protein” also comprises NS1-VP1 fusion proteins. NS1-VP1 fusion proteins comprise any NS1-VP1 fusion protein which exhibits the biological activity of both protein partners. Preferably, the NS1 protein corresponds to the N-terminal partner of the fusion protein. DNA sequences encoding such proteins can be designed by the person skilled in the art by well known methods. The person skilled in the art is also in a position to design DNA sequences encoding a fusion protein, wherein the NS1- and VP1-protein, respectively, is (are) truncated but still active.
- Assays for monitoring the biological activities of the proteins (VP1; PLA2-activity) are well known to the person skilled in the art and can be carried like measurements of arachidonic acid release (Balsinde et al., PNAS USA 95 (1998), 7951-7956) or production of prostaglandin E2 (Newton et al., 1998 , IBC 48, 32312-21) or as described in Example 2, below.
- In a preferred embodiment, the VP1 protein is fused to a carrier protein allowing, e.g., to detect the expression of the VP1 protein in a host cell. Particularly preferred are the carrier proteins green fluorescent protein (GFP), NS1, IL-2, IP10, Cytatines, Cro, or signaling peptides targeting the protein to distinct locations within the cell.
- In a more preferred embodiment, the VP1 protein (or the VP1 partner of the fusion protein) is a truncated protein which still exhibits the desired biological activity. Such truncated versions of the VP1 protein can be generated by the person skilled in the art according to standard methods. The biological activity of the VP1 fragments can be assayed, e.g. by the method described in Example 2, below.
- In an even more preferred embodiment, the truncated VP1 protein comprises the VP1 domain exhibiting phospholipase A activity. This activity is localised within the pecific N-terminal part of the VP1 protein (residues 1 to 142) (see FIG. 2; Zadori et al. (2000), VIIIth Parvovirus Workshop Mont Tremblant, Quebec, Canada.)
- A further subject matter of the present invention relates to (a) DNA sequence(s) encoding the proteins of the composition of the invention described above.
- A DNA sequence according to the present invention can be present in a vector and expression vector, respectively. A person skilled in the art is familiar with examples thereof. In the case of an expression vector forE. coli these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b, T7 based expression vectors and pQE-8. For the expression in yeast, e.g. pY100 and Ycpad1 have to be mentioned while e.g. pKCR, pEFBOS, cDM8, pMSCND, and pCEV4 have to be indicated for the expression in animal cells. The baculovirus expression vector pAcSGHisNT-A is especially suitable for the expression in insect cells.
- In a preferred embodiment, the vector containing the DNA sequence(s) according to the invention is a virus, e.g. an adenovirus, vaccinia virus, an AAV virus or a parvovirus, such as MVM or H-1, a parvovirus being preferred. The vector may also be a retrovirus, such as MOMULV, MoMuLV, HaMuSV, MUMTV, RSV or GaLV. Suitable promoters include the strong constitutive human or mouse cytomegalovirus (CMV) immediate early promoter, the inducible P38 parvovirus promoter, the parvovirus P4 promoter and tissue and tumour specific promoters.
- For constructing expression vectors which contain the DNA sequence(s) according to the invention, it is possible to use general methods known in the art. These methods include e.g. in vitro recombination techniques, synthetic methods and in vivo recombination methods as described in Sambrook et al., supra, for example.
- Furthermore, the present invention relates to host cells which contain the above described vectors. These host cells include bacteria, yeast, insect and animal cells, preferably mammalian cells. TheE. coli strains HB101, DH1, x1776, JM101, JM109, BL21, XL1Blue and SG 13009, the yeast strain Saccharomyces cerevisiae and the animal cells L, A9, 3T3, FM3A, CHO, COS, Vero, HeLa and the insect cells sf9 are preferred. Methods of transforming these host cells, of phenotypically selecting transformants and of expressing the DNA according to the invention by using the above described vectors are known in the art.
- The present invention also relates to a method of producing the composition of the invention comprising the culturing of the transformant described above under suitable conditions and isolating the protein(s) of the composition from the transformant or the medium. Methods for culturing said transformants, isolating and purifying the protein(s) are well known to the person skilled in the art.
- Moreover, the present invention relates to a pharmaceutical composition comprising the above described compounds. For administration these compounds are preferably combined with suitable pharmaceutical carriers. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose. Administration of the composition may be effected by different ways, e.g. by intravenous, intraperetoneal, subcutaneous, intramuscular, topical or intradermal administration. The route of administration, of course, depends on the nature of the disease, e.g. tumour, and the kind of compound(s) contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends on many factors, including the patient's size, body surface area, age, sex, the particular compound to be administered, time and route of administration, the kind of the tumour, general health and other drugs being administered concurrently.
- The composition of the present invention can be administered in the form of proteins (protein injection or protein delivery into the desired tumour cells) or (a) genetic element(s) encoding said proteins, supplied as free molecules or through a viral, e.g. parvoviral, or non-viral vector. Suitable vectors and methods for in vitro- or in vivo-gene therapy are described in the literature and are known to the persons skilled in the art; see, e.g., WO 94/29469 or WO 97/00957. The DNA sequences encoding the proteins of the composition of the present invention can be administered directly to the target site, e.g., by ballistic delivery, as a colloidal dispersion system or by catheter to a site in artery. The colloidal dispersion systems which can be used for delivery of the above DNA sequences include macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, (mixed) micelles, liposomes and lipoplexes. The preferred colloidal system is a liposome. The composition of the liposome is usually a combination of phospholipids and steroids, especially cholesterol. The skilled person is in a position to select such liposomes which are suitable for the delivery of the desired DNA molecule. Organ-specific or cell-specific liposomes can be used, e.g. in order to achieve delivery only to the desired tissue. The targeting of liposomes can be carried out by the person skilled in the art by applying commonly known methods. This targeting includes passive targeting (utilising the natural tendency of the liposomes to distribute to cells of the RES in organs which contain sinusoidal capillaries) or active targeting (for example by coupling the liposome to a specific ligand, e.g., an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods). In the present invention monoclonal antibodies are preferably used to target liposomes to specific tumours via specific cell-surface ligands.
- The treatment can be given to cell cultures or organisms, e.g. tumour bearing organisms. Should both proteins of the present invention be administered as separated genetic elements, time intervals between their respective administration can be applied. Alternatively, stably transfected cell lines expressing the VP1 protein can be produced. In the absence of NS1, the VP1 component is well tolerated by host cells over extended periods of time. The cytolytic effect is exerted only when the VP1 component is coexpressed with the NS1 component. It is, thus, possible to select tumour cell lines that stably express the VP1 component and contain (or not) an inducible clone of the NS1 component that is kept silent. Upon NS1 expression (as a result of NS1 gene transfer or induction) the tumour cells get lyzed, which can be achieved in vitro or in vivo (after transplantation of VP1 expressing cells) in order to trigger the release, uptake and presentation of tumour-associated antigens. Moreover, the composition of the invention or the corresponding DNA sequences can be applied in combination with other agents (such as cytokines) in gene and cancer therapy approaches.
- Finally, the present invention relates to the use of the above described compounds (protein composition, DNA sequences or expression vectors) for the preparation of a toxin for treating tumoral diseases.
- FIG. 1: A9 cells grown on Spot-Slides (NeoLab. Heidelberg, Deutschland) were transfected with the indicated constructs (100 ng/well) using 1 μL Lipofectamine (GibcoBRL, Karlsruhe, Deutschland). Transfected, living cells were identified by their green fluorescence and monitored in daily intervals using a reverse angle fluorescence Microscope (Leica IL2).
- (A) Photographs of fluorescent, transfected cells obtained after 2, 4, 5 and 6 days post transfection.
- (B) Statistical evaluation of NS1/VP1 toxicity. Transfected, GFP expressing (fluorescent) cells were counted at daily intervals and their survival was expressed as percentage of the number of fluorescent cells at
day 2 post transfection. Schematic presentation of the effector constructs expressing PLA2 (the active domain of the VP1 polypeptide) and/or NS1 parvovirus MVM. Both effector genes are expressed under the control of the parvoviral P4 promoter. To monitor cells containing transfected DNA, the gene for the green fluorescent protein was fused to the PLA2 domain. The phosphorylation site mutant NS1:S473A (Dettwiler et al., J.Virol. 73 (1999), 7410-7420) was chosen as a representative non-toxic NS1 mutant. Mutant PLA2 was generated by PCR replacing the HD-motif (aa 41/42), i.e. the active site of the PLA2 enzyme, by methionine residues. Toxicity assay was carried out according to Corbau et al., Virology 278 (2000), 151-167. - As shown in (A) and (B), wild type NS1 and the PLA2-domain of VP1 acted synergistically in that this cytotoxicity of coexpressed active polypeptides was in comparison with the effect of each effector protein alone, as revealed by the disappearance of fluorescent/transfected cells.
- FIG. 2: Schematic representation of the Darvovirus VP proteins
- (A) VP1, the large 83 kDa capsid protein comprises 716 amino acids while VP2 lacks the 142 N-terminal amino acids and starts at methionine 143 due to alternative splicing of the precursor mRNAs. The VP1 unique region is represented as a hatched box.
- (B) Blow-up of the VP1-specific region comprising amino acids 1 to 142 of the VP1 protein. The four motifs showing homology to cellular PLA2s are indicated as crossed regions and the corresponding amino acid sequences of VP1 are given on the bottom. The putative active site for PLA2-activity is indicated by capitals.
- FIG. 3: Schematic representation of examples of VP1 and VP1 variants designed for use of the present invention
- (A) VP1 deletion mutants of various sizes
- (B) VP1 fusion peptides using “carrier”-polypeptides Examples of cassettes for the expression of VP1-variants to obtain synergistic effects together with NS1
- FIG. 4
- The experiment involves the use of the Promega kit “CytoTox 96®” non-radioactive cytotoxicity assay (Promega, Mannheim, Deutschland). LDH is a cytosolic enzyme that is released upon cell lysis. Released LDH is measured using an enzymatic assay which results in the conversion of a tetrazolium salt (INT) into a red formazan product. The colour intensity, measured with a standard 96 well plate reader at 490 nm, is proportional to the number of lysed cells. Experiments were performed in 96 well plates containing 2000 mouse A9 cells per well. Infection was carried out 24 hours after spreading of the cells at a multiplicity of 10 infectious units of virus per cell. Culture medium was collected 6 days after transfection and directly tested for LDH activity as described by the manufacturer. The total amount of LDH in the cells stands for 100%
- (B) Schematic representation of VP1 constructs used for the LDH assay. Their construction is detailed in Example 1C.
- The present invention is explained by the examples.
- The coding sequence for the VP1-GFP fusion protein was obtained by chimeric polymerase chain reaction (PCR) using the
primer pair 5′-ATG ACT CCA TGG CGC CTC CAG CTA AAA AGA-3′ (A) and 5′-TCG CCC TTG CTC ACC ATC GTT TGA CTC CTT TGC TG-3′ (B) using as template pTM1-VP1 to obtain the coding sequence for the VP1-specific domain of parvovirus VP-proteins. Theprimer pair 5′-AGG AGT CAA ACG ATG GTG AGC AAG GGC GAG GAG-3′ (C) and 5′-ACG GTC TCG AGT AGC GAC CGG CGC TCA GTT GG-3′ (D) with pEGFP (Clontech, Heidelberg, Deutschland) as a template was used to obtain the GFP encoding sequence. In a second PCR reaction the VP1- and GFP-fragments were annealed due to overlapping sequences and further amplified using primers A and D. After amplification the PCR product was digested with the restriction endonucleases NcoI and XbaI and ligated into the similarly cleaved vector pDB-MVMp; see FIG. 1C. pDB-MVMp constitutes an infectious molecular clone of MVMp (Kestler et al., Hum. Gene Ther. 10 (1999), 1619-1632). - The construct constitutes an eukaryotic expression vector under the control of the parvovirus P4 promoter (S-phase/transformation regulated). The coding sequence for the NS1-VP1 fusion protein was obtained by chimeric PCR using the
primer pair 5′-GGT CAA TCT ATT CGC ATT GAT-3′ (A) and 5′-GAG GCG CCA TGT CCA AGT TCA GCG GCT CGC-3′ (B) for amplification of the template pTM1-NS1 Nuesch et al., Virology 191 (1992), 406-416) to obtain the full-length NS1 fragment. Theprimer pair 5′-GAA CTT GGA CAT GGC GCC TCC AGC TAA AAG-3′ (C) and 5′-ATA CGC CCG GGC TAG GTT TGA CTG CTT TGC TGT-3′ (D) with pTM1-VP1 as a template was used for obtaining the VP1 coding sequence. In a second round of PCR the two fragments were combined using primers A and D. After amplification the PCR product was digested with the restriction endonucleases XhoI and SmaI and ligated into XhoI and StuI digested vector pTHis-NS1 (Nuesch et al., Virology 209 (1995), 122-135). To obtain pP4-NS1-VP1, the coding sequence of the NS1-VP1 variant was amplified by PCR using an N-terminal primer containing a SmaI restriction site together with a C-terminal primer containing an XbaI cleavage site. This SmaI to XbaI NS1-VP1 fragment wad then transferred into EcoRV and XbaI cleaved pP4-GFP. Clone pP4-NS1-VP1 was deposited on May 15, 2001, with the DSMZ under accession number DSM 14300 according to the regulations of the Budapest treaty. - To obtain pP4-NS1-P4-VP1-GFP used for transfection experiments, the PmeI to XbaI fragment of pP4-VP1-GFP (or for controls pP4-GFP, pP4-mPLA-GFP) was transferred into the StuI and XbaI cleaved pDB-MVMp or pDB-NS1:S473A (Corbau et al., Virology 278 (2000), 151-167).
- To obtain pP4-NS1+2-P4-VP1-GFP recombinant MVM virus; the P4-VP1-GFP fragment was amplified using a
primer 5′-ATA CGA GAT CTG TTT AAA CCA AGG CGC GAA AAG G-3′ within the P4 promoter region containing an N-terminal BglII cleavage site and primer D wihtin the C-terminus of GFP harbouring an XbaI site. This BglII to XbaI fragment was then cloned into the BglII and XbaI cleaved capsid region of pDB-MVMp. Clone pP4-NS1+2-P4-VP1-GFP was deposited on May 15, 2001, with the DSMZ under accession number DSM 14301 according to the regulations of the Budapest treaty. - Similarly, the BglII to XbaI fragments of P4-GFP and P4-mPLA-GFP were transferred into the infectious DNA clone of MVMp.
- A9 cells grown on Spot slides (Neolab) were transfected with the constructs described in Example 1, above, and shown in FIGS. 1C and 3 expressing the GFP (fusion) proteins using lipofectamine. Fluorescent cells were monitored in daily intervals for their overall structure. From the results shown in FIG. 1B it can be concluded that NS1 and VP1 fusion proteins act synergistically to kill the transfected A9 cells. Experimental details are given in the legend of FIG. 1.
- A9 cells were transduced with various multiplicities of recombinant parvoviruses containing VP1-variants or mutants thereof. In daily intervals the release of endogenous LDH (lactate dehydrogenase) was measured using commercial kits in order to obtain measurements for cytolysis. Experimental details are given in the legend of FIG. 4.
-
1 9 1 30 DNA Artificial Sequence Synthetic Construct 1 atgactccat ggcgcctcca gctaaaaaga 30 2 35 DNA Artificial Sequence Synthetic Construct 2 tcgcccttgc tcaccatcgt ttgactcctt tgctg 35 3 33 DNA Artificial Sequence Synthetic Construct 3 aggagtcaaa cgatggtgag caagggcgag gag 33 4 32 DNA Artificial Sequence Synthetic Construct 4 acggtctcga gtagcgaccg gcgctcagtt gg 32 5 21 DNA Artificial Sequence Synthetic Construct 5 ggtcaatcta ttcgcattga t 21 6 30 DNA Artificial Sequence Synthetic Construct 6 gaggcgccat gtccaagttc agcggctcgc 30 7 30 DNA Artificial Sequence Synthetic Construct 7 gaacttggac atggcgcctc cagctaaaag 30 8 33 DNA Artificial Sequence Synthetic Construct 8 atacgcccgg gctaggtttg actgctttgc tgt 33 9 34 DNA Artificial Sequence Synthetic Construct 9 atacgagatc tgtttaaacc aaggcgcgaa aagg 34
Claims (32)
1. A composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
2. The composition of claim 1 (a), wherein the VP1 protein is fused to a carrier protein.
3. The composition of claim 2 , wherein the carrier protein is green fluorescent protein (GFP)
4. The composition of claim 1 , wherein the VP1 protein is a truncated VP1 protein.
5. The composition of claim 4 wherein the truncated VP1 protein comprises the VP1 domain exhibiting phospholipase A activity.
6. A DNA sequence coding for the composition of claim 1 .
7. An expression vector comprising the DNA sequence according to claim 6 .
8. The expression vector of claim 7 , which is a parvovirus vector.
9. The expression vector of claim 8 , which is pP4-NS1-VP1 (accession number DSM 14300) or pP4-NS1+2-P4-VP1-GFP (accession number DSN 14301)
10. A transformant containing the expression vector according to claim 7 .
11. A method of producing a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein, comprising:
culturing a transformant comprising an expression vector comprising a DNA sequence encoding for at least one proteins according to claim 1 under suitable conditions and isolating the protein(s) of the composition from the transformant or the medium.
12. A pharmaceutical composition comprising the composition according to claim 1 .
13. A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 1 .
14. Use of the DNA sequence according to claim 6 for the preparation of a vector for gene therapy.
15. A composition consisting of (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
16. The composition of 2, wherein the VP1 protein is a truncated VP1 protein.
17. The composition of 3, wherein the VP1 protein is a truncated VP1 protein.
18. A DNA sequence coding for the composition of claim 2 .
19. An expression vector comprising the DNA sequence according to claim 18 .
20. The expression vector of claim 19 , which is a parvovirus vector.
21. A DNA sequence coding for the composition of claim 5 .
22. An expression vector comprising the DNA sequence according to claim 21 .
23. The expression vector of claim 22 , which is a parvovirus vector.
24. A pharmaceutical composition comprising the composition according to claim 4 .
25. A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 4 .
26. A pharmaceutical composition comprising the composition according to claim 5 .
27. A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 5 .
28. A pharmaceutical composition comprising the DNA sequence according to claim 6
29. A method of treating tumoral diseases comprising: administering an effective amount of the DNA sequence according to claim 6 .
30. A DNA sequence coding for the composition of claim 5 .
31. A pharmaceutical composition comprising the DNA sequence according to claim 30 .
32. A method of treating tumoral diseases comprising: administering an effective amount of the DNA sequence according to claim 30.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/570,913 US8450289B2 (en) | 2001-07-10 | 2009-09-30 | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01116856.4 | 2001-07-10 | ||
EP01116856A EP1275658B1 (en) | 2001-07-10 | 2001-07-10 | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
PCT/EP2002/007706 WO2003006067A2 (en) | 2001-07-10 | 2002-07-10 | Composition comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/570,913 Division US8450289B2 (en) | 2001-07-10 | 2009-09-30 | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040208886A1 true US20040208886A1 (en) | 2004-10-21 |
Family
ID=8178011
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/483,234 Abandoned US20040208886A1 (en) | 2001-07-10 | 2002-07-10 | Composition comprising a parvovirus vp1- variant and a parvovirus ns1 protein for induction of cytolysis |
US12/570,913 Expired - Lifetime US8450289B2 (en) | 2001-07-10 | 2009-09-30 | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/570,913 Expired - Lifetime US8450289B2 (en) | 2001-07-10 | 2009-09-30 | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
Country Status (6)
Country | Link |
---|---|
US (2) | US20040208886A1 (en) |
EP (1) | EP1275658B1 (en) |
AT (1) | ATE345352T1 (en) |
AU (1) | AU2002336926A1 (en) |
DE (1) | DE60124523T2 (en) |
WO (1) | WO2003006067A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029751A1 (en) * | 2001-07-10 | 2010-02-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Compositions comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis |
US20150216964A1 (en) * | 2012-09-10 | 2015-08-06 | Merial, Inc. | Attenuated Parvovirus Vaccine for Muscovy Duck Parvovirus and Goose Parvovirus (Derzsys Disease) |
US9700588B2 (en) | 2010-07-07 | 2017-07-11 | Deutsches Krebsforschungszentrum | Use of parvovirus for eliminating cancer stem cells (CSCs) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1473306A1 (en) * | 2003-04-30 | 2004-11-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion polypeptide suitable as a cytotoxin |
EP1791858B1 (en) | 2004-09-24 | 2010-04-21 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
EP3738972A1 (en) | 2019-05-13 | 2020-11-18 | Deutsches Krebsforschungszentrum | Parvolysine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458362B1 (en) * | 1996-01-02 | 2002-10-01 | Institut Pasteur | Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE520177C2 (en) * | 1998-11-24 | 2003-06-03 | Kristina Broliden | Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells |
EP1275658B1 (en) * | 2001-07-10 | 2006-11-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
-
2001
- 2001-07-10 EP EP01116856A patent/EP1275658B1/en not_active Expired - Lifetime
- 2001-07-10 AT AT01116856T patent/ATE345352T1/en not_active IP Right Cessation
- 2001-07-10 DE DE60124523T patent/DE60124523T2/en not_active Expired - Lifetime
-
2002
- 2002-07-10 WO PCT/EP2002/007706 patent/WO2003006067A2/en not_active Application Discontinuation
- 2002-07-10 US US10/483,234 patent/US20040208886A1/en not_active Abandoned
- 2002-07-10 AU AU2002336926A patent/AU2002336926A1/en not_active Abandoned
-
2009
- 2009-09-30 US US12/570,913 patent/US8450289B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458362B1 (en) * | 1996-01-02 | 2002-10-01 | Institut Pasteur | Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029751A1 (en) * | 2001-07-10 | 2010-02-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Compositions comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis |
US8450289B2 (en) | 2001-07-10 | 2013-05-28 | Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
US9700588B2 (en) | 2010-07-07 | 2017-07-11 | Deutsches Krebsforschungszentrum | Use of parvovirus for eliminating cancer stem cells (CSCs) |
US10525091B2 (en) | 2010-07-07 | 2020-01-07 | Deutsches Krebsforschungszentrum | Use of parvovirus for eliminating cancer stem cells (CSCs) |
US20150216964A1 (en) * | 2012-09-10 | 2015-08-06 | Merial, Inc. | Attenuated Parvovirus Vaccine for Muscovy Duck Parvovirus and Goose Parvovirus (Derzsys Disease) |
US9555098B2 (en) * | 2012-09-10 | 2017-01-31 | Merial Inc. | Attenuated parvovirus vaccine for Muscovy duck parvovirus and goose parvovirus (Derzsys disease) |
US9913896B2 (en) | 2012-09-10 | 2018-03-13 | Merial, Inc. | Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease) |
Also Published As
Publication number | Publication date |
---|---|
DE60124523T2 (en) | 2007-09-06 |
EP1275658A1 (en) | 2003-01-15 |
WO2003006067A2 (en) | 2003-01-23 |
US20100029751A1 (en) | 2010-02-04 |
WO2003006067A3 (en) | 2003-05-08 |
EP1275658B1 (en) | 2006-11-15 |
ATE345352T1 (en) | 2006-12-15 |
US8450289B2 (en) | 2013-05-28 |
AU2002336926A1 (en) | 2003-01-29 |
DE60124523D1 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8450289B2 (en) | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis | |
ES2936474T3 (en) | Construction of the chimeric antigen receptor directed to the cd20 antigen and identification activity of modified T cells thereof | |
US20230322873A1 (en) | Methods to produce rod-derived cone viability factor (rdcvf) | |
JP5873863B2 (en) | Modified parvovirus with enhanced anti-tumor effect | |
Alvisi et al. | Tumor-specific nuclear targeting: promises for anti-cancer therapy? | |
CN101230335B (en) | Herpes simplex virus and recombinant virus as well as host cell, and medicinal combination thereof | |
Corbau et al. | Phosphorylation of the viral nonstructural protein NS1 during MVMp infection of A9 cells | |
CN101230334B (en) | Herpes simplex virus and recombinant virus as well as host cell and medicinal combination thereof | |
US6605467B2 (en) | Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine | |
Sui et al. | The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting | |
WO2022057904A1 (en) | Combination of oncolytic virus and modified immune cells for treatment of tumors | |
CN101374853B (en) | Methods and compositions for cancer therapy using a novel adenovirus | |
EP1370661A2 (en) | T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy | |
EP1077260B1 (en) | Parvovirus NS1 variants | |
US20240123004A1 (en) | Oncolytic virus for systemic delivery and enhanced anti-tumor activities | |
DE19925199A1 (en) | Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy | |
US20200123204A1 (en) | Recombinant oncolytic viruses for treatment of metastatic cancers | |
Shimizu et al. | Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma | |
EP0830452A1 (en) | Immune-evading proteins | |
ES2548396T3 (en) | Modified rodent parvovirus capable of spreading and spreading in human gliomas | |
CN101302256A (en) | Novel recombinant fusion molecule and antineoplastic treatment function thereof | |
US8598326B2 (en) | Polynucleotide encoding a fusion polypeptide suitable as cytotoxin | |
CN100387716C (en) | Preparation of KTV series products for inhibiting tumor cell growth and use | |
KR20240050428A (en) | Chimeric Antigen Receptor (CAR) T Cell Therapy Platform | |
Dau | The role of cell-penetrating peptides in the induction of T cell responses by virus-like particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAEFFLER, LAURENT;NUESCH, JURG;ROMMELAERE, JEAN;REEL/FRAME:015163/0752 Effective date: 20040209 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |